In the pathogenesis of systemic lupus erythematosus (SLE), impaired T helper cell (Th) subgroups and regulatory T cells (T-reg) are imbalanced. It suppresses the immune response to autoantigens and prevents autoimmune diseases. Although most of the studies have shown that the majority of peripheral T-reg cells are reduced in active disease, there are also studies showing that they are either elevated or not effective. Our aim is to determine whether there is a difference between T-reg and Th-17 levels in active and inactive SLE patients and to demonstrate the effects of these cells on disease pathogenesis. 21 SLE patients without active infection were included. Erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), complement (C)3, C4, anti-ds-DNA levels, SLEDAI values were recorded in terms of organ and system involvement, hemogram results, disease activation. SLEDAI≥6 were considered active disease. Concurrent peripheral blood Th-17 and T-reg levels were studied. 15 healthy control subjects were included in the study. 19 of the patients were women, the mean age was 37.3 ± 12.9 years and mean duration of disease was 7.9 ± 1.29 years. Hematologic involvement was present in 15 (71.4%) of the patients, renal involvement in 17 (81%) and joint involvement in 7 (42.9%). Both T-reg cells and CD4+IL17+ cell levels were significantly higher in SLE group compared to SLE in terms of CD4+CD25+T-reg, CD4+FOXP3+T-reg, CD4+CD25+FOXP3+T-reg (p=0.011, p=0.001, p=0.001 and p=0.040, respectively). When the patients were compared according to SLEDAI as active (n= 12) and inactive (n=9), there was no significant difference between the two groups in terms of Th17 and T-reg levels. However, in the inactive period, the levels of CD4+FOXP3+T-reg and CD4+CD25+FOXP3+Treg cells tended to increase compared to the active period. In the literature, the number of T-reg studies in SLE is small and the results are contradictory. In the majority of studies, it was determined that the number of T-regs decreased and that the function deteriorated and that these cells were in an increasing tendency with treatment. In conclusion, in our study, all patients with SLE were under treatment and the T-reg cells could be stimulated and higher levels than the control group could have been detected. In order to explain this situation, a similar study is needed in pre-treatment, post-treatment, and activation and remission periods in patients with SLE immunosuppressive naive patients with more patient numbers.